US court prevents Dr Reddy’s Laboratories from selling opioid dependence treatment drug

Home Markets US court prevents Dr Reddy’s Laboratories from selling opioid dependence treatment drug
US court prevents Dr Reddy’s Laboratories from selling opioid dependence treatment drug

NEW DELHI: Shares of Dr Reddy's Laboratories would be in focus on Monday morning after the New Jersey District Court granted a preliminary injunction against the domestic drugmaker on sale of a generic version of Indivior's prescription medicine Suboxone in the US market. The drug is used for treatment of opioid dependence.

The court has prevented Dr Reddy's from re-launching its generic product until the patent litigation by Indivior is concluded or until it prevails on an appeal of this injunction, a statement by CEO of Indivior, Shaun Thaxter read.

Dr Reddy's was selling generic product in the US market prior to the grant of a temporary restraining order (TRO) on June 15. The TRO remains in place, an Indivior note read.

The court has also ordered the parties to submit a final proposed injunction order on Monday. It has asked Indivior to post a bond to provide security to Dr Reddy's should the court conclude at the end of patent litigation that the patent is invalid or not infringed.

Indivior expects a $25 million dent on its revenues due to the product by Dr Reddy's before the TRO came into effect .

Original Article

Leave a Reply

Your email address will not be published.